Answers are grounded in this paper and cite their sources.
Liver-targeted AGT siRNA suppresses circulating and brain Ang II in the DOCA-salt model without lowering blood pressure, suggesting brain Ang II alterations rely on hepatic AGT and do not drive hypertension in this model.
Dear Editor,We thank Dr. Ferrario and colleagues for their interest in our work. They suggest that we cannot conclude that liver-targeted angiotensinogen (AGT) small interfering (si)RNA lowers brainstem angiotensin (Ang) II levels, and that brain-derived AGT likely contributes to brain Ang II production after all, for instance after AGT siRNA treatment.We note that the deoxycorticosterone acetate (DOCA)-salt hypertension model is generally believed to involve up-regulation of the brain renin–angiotensin system (RAS), while the circulating RAS is suppressed [1,2]. Although originally this was attributed to up-regulated brain levels of renin and/or prorenin, when quantifying brain renin/prorenin after DOCA-salt, it was actually observed that their levels decreased in parallel with those in blood [3]. Moreover, in absolute terms the brain renin and prorenin levels were excessively low, and at most represented renin and prorenin in trapped blood. Thus, essentially, there is no renin or prorenin in the brain. This leaves the question what enzyme, if any, would be responsible for AGT cleavage in the brain. If proposing brain Ang generation, a convincing candidate is needed. Yet, no alternative AGT-cleaving enzyme has been discovered in the brain until today.In the current paper we focused on AGT and Ang II, making use of liver-targeted AGT siRNA to determine which AGT (liver- or brain-derived) determines brain RAS activity [4]. First, we observed that DOCA-salt did not increase brainstem Ang II: instead, brainstem Ang II became undetectable in five out of seven rats. This therefore parallels what was observed for renin, and argues against the concept of selective brain RAS up-regulation after DOCA-salt. It is important to mention that studies reporting a rise in brain Ang levels in the DOCA-salt model made use of commercial kits [2], which unlike our LC-MS/MS method, have recently been suggested to result in unreliable measurements [5].Secondly, we observed that treatment with AGT siRNA increased brain AGT expression in DOCA-salt rats, but did not up-regulate brain Ang II—in fact, brainstem Ang II had now become undetectable in 100% of the animals, in parallel with the disappearance of circulating Ang II. We would like to point out that the significance in Figure 2B of reference [4] refers to the difference in brainstem Ang II levels between control rats (i.e., rats not treated with DOCA-salt) and rats treated with DOCA-salt + AGT siRNA. Thus, we do not claim that AGT siRNA lowers brainstem Ang II on top of its lowering by DOCA-salt. Indeed, claiming such a difference would have been very hard, since DOCA-salt had already lowered brainstem Ang II to undetectable levels in most animals. However, it is important to note that despite the disappearance of brain Ang II during DOCA-salt + AGT siRNA blood pressure remained elevated.Dr. Ferrario now suggests that we likely have missed an AGT siRNA-induced increase in brain Ang II (related to the rise in brain Agt expression), and that we should have used ‘more sensitive procedures’ to detect it. We stress that despite the rise in Agt mRNA levels, there was no change in brain AGT protein levels. Furthermore, when treating the DOCA-salt animals with spironolactone, we actually did observe rises in brain Ang II, in parallel with rises in circulating Ang II. Importantly, spironolactone normalized blood pressure, illustrating that the rises in brain Ang II during exposure to this drug apparently did not induce hypertension. These data confirm that our method is sensitive enough to allow the detection of a rise in brain Ang II levels in the DOCA-salt model. In fact, to the best of our knowledge, it is among the most sensitive in the world, while brain Ang levels are among the lowest in the body [6,7]. Our data clearly show that under all circumstances, the alterations in brain Ang II fully resemble those in blood (and thus rely on AGT of hepatic origin), and have no relationship with blood pressure in the DOCA-salt model. They also did not correlate with brain Agt expression.Dr. Ferrario subsequently suggests that it is unlikely that AGT siRNA crosses the blood–brain barrier. We fully agree, and stress that its GalNAc conjugate allows accumulation in the liver only [8]. This is supported by Figure 1A of reference [4], which shows that only liver Agt mRNA was silenced by 98 ± 1%, while expression was not lowered in brainstem, kidney and adipose tissue of AGT siRNA-treated rats.Finally, it is implied that there may be unknown functions of the non-Ang coding part of AGT, des-Ang I-AGT. This may be true. However, after AGT siRNA treatment we observed an identical drop in intact AGT and des-Ang I-AGT [9], implying that this treatment fully suppresses AGT transcription, i.e., it does not result in selective des-Ang I-AGT up-regulation. Hence, the most likely explanation of its hypotensive effects remains Ang II suppression due to the inability of AGT transcription.The authors declare that there are no competing interests associated with the manuscript.
No takes yet. Share an insight, caveat, or question.
Uijl et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: